CN108069889B - Synthesis method of azetidine-3-formic acid - Google Patents

Synthesis method of azetidine-3-formic acid Download PDF

Info

Publication number
CN108069889B
CN108069889B CN201611010633.6A CN201611010633A CN108069889B CN 108069889 B CN108069889 B CN 108069889B CN 201611010633 A CN201611010633 A CN 201611010633A CN 108069889 B CN108069889 B CN 108069889B
Authority
CN
China
Prior art keywords
azetidine
intermediate product
formic acid
acid
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201611010633.6A
Other languages
Chinese (zh)
Other versions
CN108069889A (en
Inventor
秦勇
陈悦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gansu Boxi Biotechnology Co.,Ltd.
Original Assignee
Shanghai Xipu Medicine Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Xipu Medicine Technology Co ltd filed Critical Shanghai Xipu Medicine Technology Co ltd
Priority to CN201611010633.6A priority Critical patent/CN108069889B/en
Publication of CN108069889A publication Critical patent/CN108069889A/en
Application granted granted Critical
Publication of CN108069889B publication Critical patent/CN108069889B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to the field of organic synthesis, in particular to a method for synthesizing azetidine-3-formic acid, which comprises the steps of reacting 2, 2-dihydroxymethylmalonic acid-1, 3-diethyl ester with benzhydrylamine after the protection of methanesulfonyl chloride, and then decarboxylating and removing the protection of benzhydryl to obtain the final product azetidine-3-formic acid. The synthesis method takes 2, 2-dimethylolmalonic acid-1, 3-diethyl ester as a raw material, is cheap and easy to obtain, reduces the cost of the whole synthesis line by more than 30 percent compared with the cost of the original synthesis line, does not adopt a highly toxic substance sodium cyanide, and has great industrial production prospect.

Description

Synthesis method of azetidine-3-formic acid
Technical Field
The invention relates to the field of organic synthesis, in particular to a synthetic method of azetidine-3-formic acid.
Background
Azetidine-3-carboxylic acid is an important intermediate, and downstream products thereof are useful in the synthesis of a variety of immunosuppressive agents, particularly in the treatment or prevention of diseases or conditions mediated by lymphocyte interactions, e.g., chinese patent No. CN101679235A discloses an azetidine derivative and its use as a prostaglandin E2 antagonist.
At present, the synthetic route of azetidine-3-carboxylic acid is as follows US 20100249399:
Figure BSA0000136233610000011
in the synthesis process, a large amount of highly toxic substance sodium cyanide is needed, the harmful effects such as poisoning and the like are caused to operators, and the generated wastewater has potential risk of polluting the environment. In addition, the initial raw material used in the route is benzhydryl-3-hydroxyazetidine, which has a high market price, so that the price of downstream products is high.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a method for synthesizing azetidine-3-formic acid, which reduces the production cost and does not use sodium cyanide.
In order to achieve the purpose, the invention is realized by the following technical scheme:
a synthetic method of azetidine-3-formic acid comprises the following synthetic route:
Figure BSA0000136233610000021
the method comprises the following steps:
(1) reacting 2, 2-dimethylolmalonic acid-1, 3-diethyl ester (A) serving as a raw material with methanesulfonyl chloride to generate an intermediate product (B);
(2) reacting the intermediate product (B) with benzhydrylamine to generate an intermediate product (C);
(3) carrying out decarboxylation reaction on the intermediate product (C) to obtain an intermediate product (D);
(4) and (3) reacting the intermediate product (D) with hydrogen under the action of a catalyst to remove benzhydryl protection, and adjusting the pH value by using alkali to obtain a target product (E), namely azetidine-3-formic acid.
Preferably, the reaction temperature in the step (1) is-15-10 ℃, and the reaction time is 12-36 h.
Preferably, the reaction temperature in the step (2) is 100-120 ℃, and the reaction time is 12-36 h.
Preferably, the reaction temperature in the step (3) is 70-100 ℃, and the reaction time is 12-36 h.
Preferably, the reaction temperature in the step (4) is 10-60 ℃, and the reaction time is 3-10 h.
Preferably, the catalyst in the step (4) is palladium hydroxide carbon.
Preferably, the pH value is adjusted in the step (4) by using a base, wherein the base is one selected from potassium carbonate, sodium carbonate and sodium bicarbonate, and the pH value is adjusted to be 6-7.
Compared with the prior art, the invention has the following advantages: the synthetic method does not adopt highly toxic substance sodium cyanide, avoids the human harm and the environmental pollution caused by the highly toxic substance sodium cyanide, takes the 2, 2-dihydroxymethylmalonic acid-1, 3-diethyl ester as the raw material, is cheap and easy to obtain, and reduces the cost of the whole synthetic line by more than 30 percent compared with the cost of the original synthetic line, thereby being beneficial to the cost adjustment of the downstream bulk drugs and having great industrial production prospect.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are some embodiments of the present invention, but not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1: synthesis of intermediate (B)
Adding 110g of 2, 2-dimethylolmalonic acid-1, 3-diethyl ester, 1.5L of dichloromethane and 150g of triethylamine into a clean 3L three-necked bottle, mechanically stirring for 10min, cooling to 0 ℃, slowly dropwise adding 115g of methanesulfonyl chloride into the three-necked bottle, controlling the temperature to be 0-5 ℃, generating a large amount of solid salt, reacting at room temperature overnight, adding 1L of water for washing the next day, layering, drying an organic layer, concentrating and drying to obtain 180g of an intermediate product (B), wherein the yield is 95.7%, and purification is not needed.
Example 2: synthesis of intermediate (C)
Adding 1.5L of toluene into a clean 3L three-necked bottle, adding 180g of the intermediate product (B) prepared in example 1, continuously adding 87g of benzhydrylamine and 150g of triethylamine, heating to 110 ℃, carrying out reflux reaction, allowing solids to be generated, refluxing overnight, stopping the reaction, filtering to remove salt, washing an organic layer, drying and concentrating to obtain 120g of the intermediate product (C), and purifying is not required.
Example 3: synthesis of intermediate (D)
120g of the intermediate (C) obtained in example 2 was added to 1L of 6N hydrochloric acid, heated to 80 ℃ and allowed to react overnight with heat preservation, with generation of gas, followed by evaporation of water the next day while taking care to prevent washing, to give a brown oily substance, and added with 300mL of acetone and heated to recrystallize, to give 78g of the intermediate (D) as a pale yellow solid. 1H-NMR Spectrum (CDCl3), delta (ppm): 3.00-3.90(5H, m), 4.95(1H, s), 7.25-7.28(2H, m), 7.33(4H, m), 7.53(4H, m).
Example 4: synthesis of target product (E)
78g of the intermediate product (D) obtained in example 3 was added to a mixture of 500mL of methanol and 100mL of water, 7g of palladium hydroxide carbon (10%) was added, hydrogen was introduced into the mixture to make the pressure of the reaction vessel reach 3 MPa, the reaction was carried out for 6 hours, the reaction was completed, the catalyst was removed by filtration, 500mL of water was added, methanol was evaporated, diphenylmethane was extracted twice with ethyl acetate, the aqueous layer was concentrated to dryness, 300mL of water was added again to the obtained solid, pH 6.7 was adjusted with potassium carbonate solid to have a turbidity phenomenon, ethyl acetate was used for extraction, the organic layer was dried, and 25g of azetidine-3-carboxylic acid, which is a solid product, was obtained by concentration to dryness, with a yield of 85%.
In summary, the embodiment of the invention has the following beneficial effects: the raw materials used in the whole synthesis line are cheap and easily available, and the cost is reduced by more than 30% compared with the cost of the original synthesis line.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Without further limitation, an element defined by the phrase "comprising an … …" does not exclude the presence of other identical elements in a process, method, article, or apparatus that comprises the element.
The above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.

Claims (1)

1. A synthetic method of azetidine-3-formic acid is characterized in that the synthetic route is as follows:
Figure FDA0002979474790000011
the method comprises the following steps:
(1) reacting 2, 2-dimethylolmalonic acid-1, 3-diethyl ester (A) serving as a raw material with methanesulfonyl chloride to generate an intermediate product (B), wherein the reaction temperature in the step is-15-10 ℃, and the reaction time is 12-36 hours;
(2) reacting the intermediate product (B) with benzhydrylamine to generate an intermediate product (C), wherein the reaction temperature in the step is 100-120 ℃, and the reaction time is 12-36 hours;
(3) carrying out decarboxylation reaction on the intermediate product (C) under the action of hydrochloric acid to obtain an intermediate product (D), wherein the reaction temperature in the step is 70-100 ℃, and the reaction time is 12-36 h;
(4) and (3) reacting the intermediate product (D) with hydrogen under the action of a catalyst palladium hydroxide carbon to remove benzhydryl protection, and adjusting the pH value to 6-7 by using potassium carbonate to obtain a target product (E), namely azetidine-3-formic acid, wherein the reaction temperature in the step is 10-60 ℃, and the reaction time is 3-10 hours.
CN201611010633.6A 2016-11-10 2016-11-10 Synthesis method of azetidine-3-formic acid Active CN108069889B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611010633.6A CN108069889B (en) 2016-11-10 2016-11-10 Synthesis method of azetidine-3-formic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611010633.6A CN108069889B (en) 2016-11-10 2016-11-10 Synthesis method of azetidine-3-formic acid

Publications (2)

Publication Number Publication Date
CN108069889A CN108069889A (en) 2018-05-25
CN108069889B true CN108069889B (en) 2021-10-01

Family

ID=62163381

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611010633.6A Active CN108069889B (en) 2016-11-10 2016-11-10 Synthesis method of azetidine-3-formic acid

Country Status (1)

Country Link
CN (1) CN108069889B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316638B1 (en) * 1998-05-26 2001-11-13 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
CN101646650A (en) * 2007-03-30 2010-02-10 塔加西普特公司 Sub-type selective azabicycloalkane derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1261858A (en) * 1979-11-16 1989-09-26 Barry R.J. Devlin Method of producing male sterility in plants
WO2002005183A1 (en) * 2000-07-06 2002-01-17 Bill Good Marketing, Inc. Systems and methods for contact management and campaign management
WO2008079028A1 (en) * 2006-12-22 2008-07-03 Industrial Research Limited Azetidine analogues of nucleosidase and phosphorylase inhibitors
CN104292142B (en) * 2013-07-17 2019-05-14 天津大地康和医药技术有限公司 A kind of de- aryl method of N- aryl-heterocyclic butane
CN105237455A (en) * 2015-10-14 2016-01-13 湖南华腾制药有限公司 Preparation method of 3-substituted azetidine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316638B1 (en) * 1998-05-26 2001-11-13 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
CN101646650A (en) * 2007-03-30 2010-02-10 塔加西普特公司 Sub-type selective azabicycloalkane derivatives

Also Published As

Publication number Publication date
CN108069889A (en) 2018-05-25

Similar Documents

Publication Publication Date Title
MX2013006883A (en) Acetic acid production method.
WO2010134425A1 (en) Method for producing aliphatic polycarbonate
EP2262771A1 (en) A method for the preparation of dabigatran
DK2188069T3 (en) Process and plant for the treatment of various waste streams
TW201620874A (en) Method for producing [epsilon]-caprolactam
MY148576A (en) Process for preparing epsilon-caprolactone
CN101735180B (en) Method for synthesizing gamma-lactone and perfume processing method thereof
EA036250B1 (en) Method for preparing intermediates for preparing azoxystrobin
RU2012153379A (en) METHOD FOR PRODUCING NEOPENTHYL GLYCOL
CN108069889B (en) Synthesis method of azetidine-3-formic acid
CN102173990A (en) Preparation method of butyl acrylate
CN103687489A (en) Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
CN102702143B (en) Method for preparing 2-acetylfuran
US10131610B2 (en) Methods of producing dicarbonyl compounds
Kim et al. A new convenient method for the generation of alkoxy radicals from N-alkoxydithiocarbamates
CN110452181A (en) The synthetic method of 2- methyl -4- amino -5- formamide methylpyrimidine
KR20220019803A (en) Continuous synthesis method of 1,1'-bicyclo[1.1.1]pentane-1,3-diethylketone-based organics
Rousseau et al. Scale-up of a chemo-biocatalytic route to (2 R, 4 R)-and (2 S, 4 S)-monatin
CN105733000A (en) Preparation method of polylactic acid film
CN104987325B (en) A kind of preparation method of voriconazole
MY158187A (en) Method for purification treatment of process water
CN104587972A (en) Preparation method and application of hydroximic acid functionalized cellulose adsorption material
WO2022084887A1 (en) A process for the preparation of chlorantraniliprole
CN112500370A (en) Method for synthesizing dimethomorph under catalysis of Lewis base
RU2396281C2 (en) N-2-(2-pyridyl)ethylchitosan and synthesis method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TA01 Transfer of patent application right

Effective date of registration: 20210927

Address after: 730900 Baiyin national high tech Industrial Development Zone, Baiyin District, Baiyin City, Gansu Province

Applicant after: Gansu Boxi Biotechnology Co.,Ltd.

Address before: 201613 Building 5, No. 255, Cao Nong Road, Songjiang District, Shanghai

Applicant before: SHANGHAI XIPU MEDICINE TECHNOLOGY Co.,Ltd.

TA01 Transfer of patent application right